Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIOLETTE: olaparib ± DNA damage repair–targeting agents in metastatic triple negative breast cancer
2024-514205-60-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial in triple-negative breast cancer (TNBC) comparing Olaparib monotherapy, Olaparib + ceralasertib and Olaparib + adavosertib (3 arms). Primary endpoints: Progression-free Survival Per Stratum (BICR) and Progression-free Survival Per Stratum (Sensitivity Analysis). Planned start Aug 2024; status: authorised.
02
Drugs
olaparibceralasertibadavosertib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2024-514205-60-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514205-60-00.